The Center for Precision Imaging at the Massachusetts General Hospital Martinos
Center/Harvard Medical School has openings for highly qualified individuals at the postdoctoral
level to work on PET molecular imaging probe/molecular therapeutics
(theranostics) development. Our Center is at the forefront of personalized imaging and
we are working to pioneer novel imaging and therapeutic agents for individualize
treatment of cancer. We have a long-standing interest in developing and translating
targeted biological PET probes for improved tumor characterization for personalizing
cancer treatment and autoimmune conditions. Over the past decade, we have
produced many PET and optical imaging probes for assessing immune system

activation, receptor imaging, imaging of the tumor microenvironment and interrogation of metabolome. Our group has led some of the first efforts to diagnose therapeutic
resistance through receptor imaging and feedback loop signaling, monitor and predict
the immune response in cancer immunotherapy and utilize targeted imaging to
determine effective therapy dosing, among others. These efforts have led to two first inhuman
imaging agents, most recently 68Ga-NOTA-hGZP for imaging granzyme B,
currently in open trials for clinical validation.
Successful candidate(s) should have a proven track record of continued
achievement and be self-motivated with strong work ethic, a commitment to teamwork
and effective communication skills. If you are interested, please contact the CPI using
the following email to umahmood@mgh.harvard.edu or directly applying to the position
here.

Strong background in biochemistry, peptide/protein engineering
Development of biological molecular probes, radiometals and/or
radiochemistry. Prior experience in cancer biology, cancer immunology and animal models of
disease is preferred.

Minimum requirement is a PhD or MD.